Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) αβ genes transduced to CD8+ T cells

Gene Therapy

Volumn 15, Issue 9, 2008, Pages 695-699

  Hiasa, A ^a   Hirayama, M ^a   Nishikawa, H ^a   Kitano, S ^a   Nukaya, I ^b   Yu, S S ^b   Mineno, J ^b   Kato, I ^b   Shiku, H ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAKARA BIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELANOMA ANTIGEN 1; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENETIC STABILITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE CLONE; MOLECULAR CLONING; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR GENE; VIRAL GENE DELIVERY SYSTEM;

ADOPTIVE TRANSFER; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; CLONING, MOLECULAR; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE THERAPY; GENES, T-CELL RECEPTOR ALPHA; GENES, T-CELL RECEPTOR BETA; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; RETROVIRIDAE; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TIME; TRANSDUCTION, GENETIC;

EID: 42149189381     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303099     Document Type: Article

References (20)

1. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E et al. NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
2. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
5. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-915.
7. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-393.
8. Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR αβ genes into primary human T lymphocytes. J Immunol 2003; 170: 2186-2194.
9. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174: 4415-4423.
10. De Plaen E, De Backer O, Arnaud D, Bonjean B, Chomez P, Martelange V et al. A new family of mouse genes homologous to the human MAGE genes. Genomics 1999; 55: 176-184.
11. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 1999; 29: 3329-3337.
12. Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005; 11: 5581-5589.
13. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984; 44: 5657-5660.
14. Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D et al Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 2005; 106: 470-476.
15. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235-243.
16. + T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005; 28: 252-257.
17. + T cells following peptide vaccination. J Immunol 2006; 176: 6340-6346.
18. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006; 116: 1946-1954.
19. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/ HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343.
20. + cytotoxic T lymphocytes. Int J Cancer 2000; 87: 553-558.